Zongertinib Drives High Response in First-Line HER2-Mutant Lung Cancer

The Missing First-Line Target in Lung Cancer

Human epidermal growth factor receptor 2 (HER2) mutations drive approximately 2 to 4 percent of non-small-cell lung cancers, yet these patients have historically lacked a dedicated first-line targeted therapy [1, 2]. While targeted treatments have transformed the management of other oncogenic drivers, patients with HER2-mutant disease typically begin treatment with standard platinum-based chemotherapy and immunotherapy [3]. Previous attempts to use pan-HER tyrosine kinase inhibitors were limited by severe off-target toxicities driven by wild-type EGFR inhibition, while newer antibody-drug conjugates are currently reserved for previously treated patients and carry risks of interstitial lung disease [4]. To address this gap, researchers have developed highly selective tyrosine kinase inhibitors engineered to target mutant HER2 while sparing wild-type EGFR [5]. A recent clinical trial now evaluates whether one of these selective agents can safely and effectively move targeted therapy into the first-line setting for this patient population.

Trial Design and Mechanism of Action

Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). To address this clinical gap, researchers evaluated zongertinib, an oral, irreversible tyrosine kinase inhibitor (a drug that binds permanently to its target enzyme to provide sustained blockade of tumor growth signals). This agent selectively inhibits HER2 while sparing wild-type epidermal growth factor receptor (EGFR), thereby minimizing the severe skin rashes and gastrointestinal toxicities that have historically limited broader pan-HER inhibitors. The researchers conducted a phase 1a-1b, multicohort trial to assess zongertinib in patients with advanced or metastatic nonsquamous HER2-mutant NSCLC. The trial was funded by Boehringer Ingelheim (Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804). Within this broader study, the investigators specifically evaluated zongertinib at a dose of 120 mg once daily in patients who had not previously received treatment (cohort 2). To measure the efficacy of this first-line intervention, the primary end point was objective response as assessed by blinded independent central review. Secondary end points included duration of response and progression-free survival, providing a comprehensive view of how long the targeted therapy could control disease progression in a treatment-naive population.

Systemic Efficacy in Treatment-Naive Patients

To evaluate the systemic efficacy of this targeted therapy in a first-line setting, the researchers analyzed data from cohort 2, where a total of 74 previously untreated patients received zongertinib at a dose of 120 mg. The primary analysis demonstrated substantial tumor shrinkage in this population. As of August 21, 2025, the percentage of patients in cohort 2 with a confirmed objective response was 76% (95% confidence interval [CI], 65 to 84). Beyond the initial tumor response, the clinical benefit proved durable over time. The median duration of response in cohort 2 was 15.2 months (95% CI, 9.8 to not evaluable). Furthermore, the median progression-free survival in cohort 2 was 14.4 months (95% CI, 11.1 to not evaluable). For practicing oncologists, achieving nearly a year and a half of median progression-free survival suggests that zongertinib offers sustained efficacy in previously untreated patients with advanced or metastatic HER2-mutant NSCLC, potentially allowing patients to delay the need for traditional cytotoxic chemotherapy.

Intracranial Activity in Brain Metastases

Because non-small-cell lung cancer frequently spreads to the central nervous system, the researchers also evaluated zongertinib in patients with active brain metastases (exploratory cohort 4). In this specific group, a total of 30 patients with active brain metastases received zongertinib at a dose of 120 mg. To determine the drug's ability to cross the blood-brain barrier and shrink central nervous system lesions, the investigators measured tumor response using standardized neuro-oncology metrics. The analysis showed that 47% of patients (95% CI, 30 to 64) in cohort 4 achieved a confirmed intracranial objective response. This outcome was formally evaluated according to Response Assessment in Neuro-Oncology Brain Metastases criteria, a standardized framework used to measure tumor shrinkage specifically in the brain. For clinicians, this demonstrated intracranial activity is highly relevant, as central nervous system involvement often drives severe neurologic morbidity and complicates treatment planning in advanced lung cancer.

Safety Profile and EGFR-Sparing Tolerability

The safety profile of zongertinib aligns with its design as a selective inhibitor that spares wild-type epidermal growth factor receptor. The researchers reported that overall, treatment-related adverse events were predominantly low-grade. Looking at the broader safety data in cohort 2, adverse events of any grade occurred in 73 patients (99%). When assessing clinical severity regardless of attribution to the study drug, the investigators noted that adverse events of grade 3 or higher occurred in 33 patients (45%). To understand the specific toxicities driven by the drug itself, the researchers isolated events directly attributed to the therapy. In cohort 2, treatment-related adverse events occurred in 67 patients (91%). Severe toxicities remained relatively uncommon, as treatment-related adverse events of grade 3 or higher occurred in 14 patients (19%). A similar tolerability profile was observed in the population with central nervous system involvement. Specifically, in cohort 4, treatment-related adverse events of grade 3 or higher occurred in 5 patients (17%). For practicing physicians, these data suggest that the targeted inhibition of mutant HER2 can be achieved without the high rates of severe, dose-limiting toxicities historically seen with broader pan-HER inhibitors, offering a more manageable daily oral regimen for patients.

References

1. Johnson ML, Soo RA, Wu Y, et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.. Journal of Clinical Oncology. 2024. doi:10.1200/jco.2024.42.16_suppl.tps8654

2. Aliaga PT, Spitaleri G, Attili I, et al. HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top. Molecules. 2025. doi:10.3390/molecules30122645

3. Evangelou C. Updates in First-Line Treatment of Advanced HER2 (ERBB2)-Mutant Non-small Cell Lung Cancer: Insights from the European Society for Medical Oncology (ESMO) Congress 2025. 2025. doi:10.33590/oncolamj/befa1660

4. Agarwal P, Gangoda R, Sharma M, Somani R, Somani N. Zongertinib: A Novel Therapeutic Advance in HER2-Mutant Non-Small Cell Lung Cancer. Indian Journal of Medical and Paediatric Oncology. 2026. doi:10.1055/s-0046-1816580

5. Heymach J, Popat S, Smit E, et al. The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.. Expert Review of Anticancer Therapy. 2026. doi:10.1080/14737140.2026.2623059